NCT05728138

Brief Summary

To check the feasibility and acceptability of Culturally adapted Cognitive Behavioral Therapy for Psychosis (CaCBTp) and Culturally Adapted Manual Assisted Brief Psychological Intervention for Self-harm (CMAP), which we have provisionally called (CMAP Plus) for individuals experiencing Suicidal Ideation (SI) in First Episode Psychosis (FEP).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 4, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 14, 2023

Completed
9 months until next milestone

Study Start

First participant enrolled

November 1, 2023

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2025

Completed
Last Updated

January 3, 2025

Status Verified

January 1, 2025

Enrollment Period

1.7 years

First QC Date

February 4, 2023

Last Update Submit

January 1, 2025

Conditions

Keywords

Self-harm, First Episode Psychosis, adaptation, problem-solving.

Outcome Measures

Primary Outcomes (2)

  • Feasibility Indicator

    feasibility will be determined by collecting data on recruitment and retention rates. The success criterion of feasibility will be to recruit \> 50% of eligible participants

    From baseline to 12th week (end of intervention)

  • Acceptability Indicator

    Intervention acceptability will be assessed using data on attendance. Criterion for acceptability is a mean attendance rate of \>70%.

    From baseline to 12th week (end of intervention)

Secondary Outcomes (7)

  • Positive and Negative Syndrome Scale

    From baseline to 12th week (end of intervention)

  • Beck Scale for Suicidal Ideation

    From baseline to 12th week (end of intervention)

  • Medication Adherence Rating Scale

    From baseline to 12th week (end of intervention)

  • Calgary Depression Scale

    From baseline to 12th week (end of intervention)

  • The Work and Social Adjustment Scale

    From baseline to 12th week (end of intervention)

  • +2 more secondary outcomes

Study Arms (2)

CMAP Plus FEP

EXPERIMENTAL

Participants with First episode of psychosis, Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT)

Behavioral: CMAP Plus CBT

treatment as usual

NO INTERVENTION

Participants in this group will continue their routine treatment as prescribed by their responsible clinician. In Pakistan TAU mostly comprise of antipsychotics with few patients having access to psychological therapies. Research staff will record the nature and intensity of the TAU for each participant

Interventions

CMAP Plus CBTBEHAVIORAL

Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months. This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management

CMAP Plus FEP

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Individuals diagnosed with, Schizophrenia or Schizoaffective disorder according to DSM-V, confirmed by treating consultant.
  • Age 18 and above years able to understand written and spoken Urdu.
  • A score of 1 (Mild- Frequent thoughts of being better off dead, or occasional thoughts of suicide.) on the Calgary depression Scale item 8 (Suicide) "Have you felt that life wasn't worth living? Did you ever feel like ending it all? What did you think you might do? Did you actually try?"
  • Individuals with a score of 3 or more on any of the positive symptoms on the Positive and Negative Syndrome Scale (PANSS) (e.g., delusions, hallucination).

You may not qualify if:

  • Any evidence of organic brain disease, clinically significant comorbid illness or learning disability. Participants deemed actively suicidal by their designated health professional.
  • Those scoring \>1 on Calgary depression Scale will be excluded and be referred to a psychiatric service.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Karwan e Hayat

Karachi, Sindh, 75600, Pakistan

RECRUITING

MeSH Terms

Conditions

Self-Injurious Behavior

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Study Officials

  • Imran Chaudhry

    Ziauddin Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 4, 2023

First Posted

February 14, 2023

Study Start

November 1, 2023

Primary Completion

June 30, 2025

Study Completion

October 30, 2025

Last Updated

January 3, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

Locations